Want to see HCWB full AI Analyst Report?
HCWB Stock Chart & Stats
$2.50
-$0.38(-13.19%)
At close: 4:00 PM EDT
$2.50
-$0.38(-13.19%)
Day’s Range― - ―
52-Week Range$1.50 - $44.10
Previous CloseN/A
Volume56.72K
Average Volume (3M)105.98K
Market Cap
$4.23M
Enterprise Value$7.30
Total Cash (Recent Filing)$1.23M
Total Debt (Recent Filing)$6.58M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Aug 07, 2026EPS Estimate
-1.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-50.94
Shares Outstanding1,596,849
10 Day Avg. Volume63,564
30 Day Avg. Volume105,978
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.74
Price to Sales (P/S)37.52
P/FCF Ratio-0.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.76
Revenue Forecast (FY)$900.00K
Bulls Say, Bears Say
Bulls Say
High Gross Margin & Revenue ReboundSustained ~97% gross margins and a TTM revenue rebound indicate strong unit economics for recognized revenue. Over a 2-6 month horizon, such high product-level margins provide a durable foundation for profitability as R&D and SG&A scale, improving leverage if clinical programs advance and drive larger revenue streams.
Regained Cell Therapy License RightsRegaining full rights to HCW9201/HCW9206 repositions the company to directly capture value in fast-growing CAR-T and NK-cell supply chains. Owning these commercial-ready reagents supports partnership or manufacturing revenues and strengthens strategic optionality, a durable asset that can be monetized or integrated into cell therapy platforms.
Positive Early Clinical Data (HCW9302)Early human data showing clinical activity and favorable tolerability for HCW9302 materially derisks the program and supports a path to a Phase 2 dose decision by year-end. Clinically validated mechanism and safety in humans strengthens the pipeline's development trajectory and long-term partner or investor interest.
Bears Say
Large Operating Cash BurnSustained operating and free cash flow deficits of roughly -$11.5M TTM indicate persistent cash consumption that will require external funding to support clinical programs. Over several months, this cash burn constrains runway, increases reliance on dilutive financings, and limits strategic flexibility for R&D and partnerships.
Balance-Sheet InstabilityMeaningful debt relative to a small equity base and a history of negative equity signal balance-sheet fragility. This structural leverage elevates refinancing and covenant risk, raises cost of capital, and can hinder long-term collaboration or licensing deals if counterparties view financial stability as uncertain.
Persistent Listing & Financing PressureOngoing Nasdaq monitoring, recent reverse splits and frequent warrant/equity actions reflect structural listing and capital-access pressure. This forces recurring capital raises and dilutive instruments, creating lasting shareholder dilution risk and governance constraints while diverting management focus to compliance and fundraising rather than purely clinical progress.
HCW Biologics News
HCWB FAQ
What was HCW Biologics’s price range in the past 12 months?
HCW Biologics lowest stock price was $1.50 and its highest was $44.10 in the past 12 months.
What is HCW Biologics’s market cap?
HCW Biologics’s market cap is $4.23M.
When is HCW Biologics’s upcoming earnings report date?
HCW Biologics’s upcoming earnings report date is Aug 07, 2026 which is in 9 days.
How were HCW Biologics’s earnings last quarter?
HCW Biologics released its earnings results on May 14, 2026. The company reported $0.37 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is HCW Biologics overvalued?
According to Wall Street analysts HCW Biologics’s price is currently Undervalued.
Does HCW Biologics pay dividends?
HCW Biologics does not currently pay dividends.
What is HCW Biologics’s EPS estimate?
HCW Biologics’s EPS estimate is -1.98.
How many shares outstanding does HCW Biologics have?
HCW Biologics has 1,596,849 shares outstanding.
What happened to HCW Biologics’s price movement after its last earnings report?
HCW Biologics reported an EPS of $0.37 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 262.018%.
Which hedge fund is a major shareholder of HCW Biologics?
Currently, no hedge funds are holding shares in HCWB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
HCW Biologics
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
HCWB Stock 12 Month Forecast
Average Price Target
$5.00
▲(100.00% Upside)
Technical Analysis
Kiora Pharmaceuticals
―
Matinas BioPharma
―
Xenetic Biosciences
―
Addex Therapeutics
―
Calidi Biotherapeutics
―
Ownership Overview
54.89% Insiders
1.55% Mutual Funds
― Other Institutional Investors
43.43% Public Companies and
Individual Investors